University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > SFGH PHP Grand Rounds > Musoke > Slides
Treatment of HIV-Infected Children in Resource-Limited Countries
Slide 1.

Treatment of HIV-Infected Children in Resource-Limited Countries
Slide 1.

Outline
Slide 1.

Epidemiology
Slide 1.

Morbidity and Mortality Prior to HAART
Slide 1.

Survival in the HAART Era
Slide 1.

Estimates of Children in Need of ARV and Cotrimoxizole (UNAIDS/UNICEF 2005)
Slide 1.

National Statistics: Uganda
Slide 1.

10-Point Management Plan: PAEDIATRIC HIV
Slide 1.

Prophylaxis for Opportunistic Infections in Sub-Saharan Africa
Slide 1.

Mortality: Children with HIV Antibiotic (CHAP) Trial
Slide 1.

Prevention of Malaria in HIV-Infected Children
Slide 1.

INH Prophylaxis
Slide 1.

Benefit of INH Prophylaxis
Slide 1.

Immunizations
Slide 1.

Challenges of Pediatric Antiretroviral Therapy in RLS
Slide 1.

WHO Guidelines for ART in Children
Slide 1.

Age-Specific Recommendations to Initiate ART
Slide 1.

Probability of Death within 1 Year by TLC in Ugandan Cohort
Slide 1.

First-Line Regimens
Slide 1.

Second-Line Regimens
Slide 1.

Problems with Specific ARVs in Children
Slide 1.

Monitoring HAART in RLS
Slide 1.

Failure in Children on HAART
Slide 1.

Decision-Making on Switching to Second-Line Therapy for Treatment Failure Based on Availability of CD4 Measurement
Slide 1.

Outcome of ART Stratified by CD4 Percentage at Baseline
Slide 1.

Distribution of Median CD4 Percentage over Time
Slide 1.

Response to HAART in Children: Mulago
Slide 1.

Median WAZ and HAZ Baseline and 12, 24, 36, 48, and 72 Weeks after Initiation of HAART
Slide 1.

Relying on Cutting Tablets in Half Is Not Always Feasible
Slide 1.

Blister Packs Make Administering of Drugs Easier
Slide 1.

Immunological Monitoring
Slide 1.

Clinical Monitoring
Slide 1.

Virologic Monitoring
Slide 1.

Clinical Diagnosis
Slide 1.

WHO Clinical Case Definition--Problems
Slide 1.

Response to HAART after sdNVP Exposure at Birth
Slide 1.

Single-Dose NVP Prophylaxis is Associated with NVP Resistance Acquisition in Infants Failing Prophylaxis--AZT and No Maternal NVP Dose May Reduce Resistance
Slide 1.

Figure 2. Time to Virologic Failure
Slide 1.

Response to NVP Containing HAART in sdNVP-Exposed vs Nonexposed Children
Slide 1.

Children Are NOT Small Adults: Clinically, Immunologically, Virologically
Slide 1.

Children Are NOT Small Adults: Drug Handling
Slide 1.

Challenges of Pediatric Antiretroviral Therapy in Resource-Poor Countries
Slide 1.

Response to HAART in Children: Mulago
Slide 1.

Image: 8-Year-Old Girl before HAART
Slide 1.

Same Girl after 6 Months of HAART
Slide 1.

ILA Program
Slide 1.

Distribution of Median CD4 Percentage over Time
Slide 1.

Log HIV RNA PCR at Baseline, 12, 24, 36, and 48 weeks
Slide 1.

Adherence Using Different Measures
Slide 1.

Distribution of Median CD4 Percentage over Time
Slide 1.

Psychosocial Support
Slide 1.

Younger Children in Peer Support Group
Slide 1.

Pediatric HIV Clinic in Mulago: Supported by Baylor College of Medicine
Slide 1.

Lessons Learnt
Slide 1.

Children's Peer Support Group: Executive Committee
Slide 1.

Major Challenges to Scaling Up Pediatric HAART
Slide 1.

Thank You
Slide 1.